1 To assess whether or not lignocaine influences baseline and frusemide-induced (5 mg kg-') plasma concentrations of arginine-vasopressin (AVP), 2 groups of rabbits received an infusion of lignocaine (130 fig min'-kg-') for 6 h. Lignocaine-induced changes in AVP plasma concentrations were substantiated by measurement of diuresis and natriuresis and hepatic plasma flow, by means of an infusion of indocyanine green (ICG) (249 fg min' kg-'). 2 Baseline plasma AVP levels were 4.9 ± 0.9 pg ml-' (+ s.e.), and following lignocaine, these values were reduced to 0.7 ± 0.1 pg ml-I (P<0.01). Frusemide increased AVP levels to 134.1 ± 73.6 pg ml' (P <0.05) and lignocaine totally prevented this increase, e.g. mean AVP levels of 2.7 pg ml-'. 3 Lignocaine enhanced baseline diuresis secondary to an increase in free water clearance; none of the experimental conditions affected the diuresis and natriuresis induced by frusemide. 4 Frusemide reduced the hepatic plasma flow and this decrease was not reversed by the infusion of lignocaine.5 It is concluded that in healthy rabbits lignocaine reduces baseline secretion of AVP and its antidiuretic effect; in addition, lignocaine prevents the rise in AVP induced by frusemide.